The use of low molecular weight heparin (LMWH) for the prevention and treatment of venous thromboembolism has been validated by numerous clinical trials and meta-analyses over the past 25 years. More recently, the possibility of extending treatment with LMWH to the arterial disease where thrombosis is a prominent feature has led to the planning of many clinical trials, several of which have been already published. LMWH has been tested in settings such as acute coronary syndromes, including myocardial infarction, surgery or percutaneous revascularization for coronary and peripheral arteries, and stroke. In most indications, LMWH has proved to be superior to or at least as effective as unfractionated heparin and it is also easier to administer.
Introduction
Low molecular weight heparin (LMWH) has been used for many years for the prevention and treatment of venous thromboembolism. The efficacy and safety of LMWH in this indication is widely documented and has been confirmed by numerous controlled clinical trials and metaanalyses. The fact that many of the pharmacological limitations of unfractionated heparin (UFH) have been overcome by LMWH has led to the idea of evaluating the applicability of LMWH in all the situations in which UFH is used.
In arterial pathologies UFH is used -although based on variable experimental evidence -in different clinical situations such as acute coronary syndromes, including acute myocardial infarction, heart surgery, vascular surgery, coronary and peripheral percutaneous revascularization (angioplasty or atherectomy, with or without stenting) and acute stroke. In almost all of these conditions, controlled studies confirmed the expected superiority of LMWH based on consistency of the dose/effect ratio, longer half-life, enhanced bioavailability, and ease of administration. 1 The aim of this review is to report on results of clinical studies performed in the various clinical settings where arterial thrombosis is a prominent feature of the disease.
LMWH could be a good substitute for UFH, but there is still no clear indication about this possibility.
A small-scale study published by Glick and colleagues 2 suggests that enoxaparin may be effective in reducing reinfarction at 1 month. In this study, for 25 days enoxaparin was given vs placebo after streptokinase + UFH. At 1 month, the endpoint of reinfarction was 4.6% vs 20% (p = 0.02).
The preliminary results of a larger study by the same author comparing enoxaparin with UFH seem to be favorable. In this study, patients were administered enoxaparin vs UFH for 4 days following treatment with streptokinase + UFH. At 48 h after the end of this therapy there was a reinfarction incidence of 0.5 vs 1.5, whereas at 3 months the incidence of death, AMI or recurrent angina was 26% vs 36%.
A recent pilot trial, the BIOMACS II, 3 investigated the efficacy of LMWH associated with thrombolysis in AMI. In this study, 101 patients who underwent thrombolysis with streptokinase were randomized to receive dalteparin subcutaneously (100 IU/kg just before thrombolysis, followed by 120 IU/kg after 12 h) or placebo. The results show that the dalteparin group tended to have a lower ECG-documented incidence of recurrent ischemia and better angiographic patency at 24 h.
Another aspect regarding the potential of LMWH in AMI was assessed by Kontny and colleagues in FRAMI, 4 a multicenter, randomized, double-blind, placebo-controlled study on the efficacy and safety of dalteparin in preventing arterial thromboembolism. A total of 776 patients were randomized to receive dalteparin (150 IU/kg every 12 h during hospitalization) or placebo, associated with thrombolysis + ASA in 91.5% and 97.6% of cases, respectively. This study assessed the formation of intracavitary thrombi (via echocardiography) or the occurrence of arterial embolism at 9 Ϯ 2 days.
The results showed a significant decrease in the combined endpoint (thrombus formation or arterial embolism): 14.2% in the LMWH group vs 21.9% in the placebo group (p = 0.03). Subanalysis highlighted a risk reduction in thrombus formation (RR = 0.63; CI 0.43-0.9; p = 0.02) in the dalteparin group, without any significant differences in arterial embolism, reinfarction or death. Unfortunately, the hemorrhagic risk increased in the dalteparin group, with 2.9% vs 0.3% major events (p = 0.006) and 14.8% vs 1.8% minor events (p Ͻ 0.001) ( Figure 1 ).
UA and non-Q-wave AMI
There are several published studies for this indication. The heparins that have been studied most extensively are nadroparin, dalteparin and enoxaparin, as compared with placebo or UFH. Four clinical trials (Gurfinkel's pilot study, 5 FRAXIS, 6 FRISC 7 and FRIC 8 ) showed the efficacy of nadroparin and dalteparin in the acute phase, without any evident long-term advantages.
The Gurfinkel pilot study 5 compared the efficacy of ASA alone, ASA + UFH (APTT-adjusted intravenous infusion), and ASA + LMWH (nadroparin 85 IU/kg twice daily subcutaneously) administered for 5-7 days. The short-term results were significantly better in the LMWH group than in the ASA alone and ASA + UFH groups. No long-term follow-up was provided.
The FRAXIS study 6 was designed to assess the efficacy and safety of a 14-day treatment with nadroparin when compared with the conventional 6-day treatment with nadroparin or UFH (already assessed in the Gurfinkel study). A second evaluation was conducted at 3 months. The cumulative endpoint was the combined incidence of MI or refractory or recurrent angina and it was the same in the three groups, both after 14 days and at 3 months. Moreover, major hemorrhages were the same at 6 days, whereas their incidence was higher in the long-term nadroparin group than in the placebo group after 14 days and at 3 months.
In the FRISC study, 7 patients were randomized to receive dalteparin (120 IU/kg twice daily for 6 days, followed by 7500 IU once a day for the next 35-45 days) or placebo. The benefit of LMWH was significant at 6 days (incidence of death and new myocardial infarction = 1.8% vs 4.8%, risk ratio 0.37, 95% CI 0.20-0.68; revascularization = 0.4% vs 1.2%, risk ratio 0.33, 95% CI 0.10-1.10) and seemed to persist at 40 days in non-smokers, whereas this benefit was not sustained 4-5 months after the end of treatment.
The FRIC study 8 4 : the dalteparin group had a significant reduction in arterial thromboembolic events (14.2 vs 21.9%; p = 0.03), but at the cost of an increased risk of major hemorrhages (2.9 vs 0.3%; p = 0.006).
compared dalteparin with UFH (APTTadjusted intravenous infusion) in an open acute phase (first
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A third large-scale study with dalteparin (FRISC II) 9 has been published very recently and its aim is to evaluate optimal duration of LMWH treatment by investigating longterm treatment efficacy. In this trial, more than 2000 patients with UA, all of whom were treated with dalteparin in the acute phase (120 IU/kg every 12 h for at least 5 days), were randomized to receive dalteparin (5000 or 7500 IU every 12 h according to gender and bodyweight) or placebo for 3 months.
The results show a significant decrease in the composite endpoint (death or AMI) at 30 days in the dalteparin group (3.1% vs 5.9%; RR 0.53; CI 0.35-0.80; p = 0.002). There was still some benefit at 3 months, but the difference was no longer significant (6.7% vs 8.0%). In the dalteparin group, there was also a significant decrease in the triple endpoint (death, AMI or revascularization) at 3 months (29.1% vs 33.4%; RR 0.87; CI 0.77-0.99; p = 0.031). Both the double and triple endpoints do not reveal any important differences between the two groups at 6 months.
Therefore, prolonged treatment with dalteparin has a beneficial effect during the first month, but this benefit decreases at 3 months and is not sustained during long-term follow-up. It should be added that the benefit of dalteparin in long-term treatment was only observed in the conservative group. 10 The authors suggested that long-term LMWH therapy can be useful in reducing the risk of events in patients waiting for invasive procedures.
Enoxaparin was investigated in two studies, ESSENCE 11 and TIMI 11B, 12 and the results were favorable in both studies. In the ESSENCE study, 3171 patients with recurrent angina or non-Q-wave myocardial infarction were randomized to receive enoxaparin subcutaneously (1 mg/kg twice daily) or UFH in a continuous infusion. The combined endpoint of death, AMI or recurrent angina at 14 days (primary endpoint) showed an event decrease in the LMWH group (16.6% vs 19.8%; OR 1.24; CI 1.04-1.49; p = 0.019), confirmed at 30 days (19.8% vs 23.3%; OR 1.23; CI 1.0-1.46; p = 0.016), without any differences in major bleeding episodes (respectively 7.0% for the UFH and 6.5% for the enoxaparin). The statistical significance of the superiority of LMWH is attributable to its effects on recurrent angina, given that the reductions in AMI and/or death -albeit notable -are not statistically different. Another advantage is the lower revascularization rate in the enoxaparin group during the first 30 days (27% vs 32.2%; p = 0.001). As opposed to many other studies, the percentage of patients treated with UFH with an effective anticoagulation proved to be high (only 17% of the patients had an APTT below the therapeutic range). It is possible that the efficacy of UFH was improved by this factor, which may thus have decreased the difference in the benefits observed with enoxaparin. 13 However, we must also consider that rapid achievement of optimal anticoagulation with UFH is sometimes problematic in clinical practice.
An economic analysis of the ESSENCE data 14 further suggests that the total medical cost (including the cost of the subsequent revascularization procedure) is lower with enoxaparin treatment than with UFH. In fact, although the cost of the treatment (drugs only) is higher for LMWH, in the USA the total medical cost (hospital, physician, drugs) for hospitalization is lower: US$11 857 for treatment with enoxaparin as opposed to US$12 620 with UFH, saving US$763 (p = 0.18). At the end of the 30-day period, the savings associated with enoxaparin amount to US$1172 (p = 0.04). A reduction of revascularization procedures in the British patients in the ESSENCE study yielded savings of £2367 for every 100 patients treated. 15 Lastly, the preliminary results of the 1-year follow-up of this study 16 suggest that the benefits of enoxaparin are maintained over the long term. The partial data (95% of the patients) show a decrease of 10.4% in the relative risk for the endpoint of death, AMI or recurrent angina (32% vs 35%) and of 14.8% in the endpoint of death or AMI (11.5% vs 13.5%) in favor of enoxaparin, associated with a lower incidence of diagnostic catheterization (55.8% vs 59.4%) and of revascularization procedures (35.9% vs 41.2%).
The TIMI 11B, 12 a randomized double-blind study, consisted essentially of two phases. The first phase involved in-hospital administration of UFH at doses that would maintain APTT at 1.5-2.5 times the control for at least 72 h, or enoxaparin (30-mg bolus followed by 1 mg/kg every 12 h) up to a maximum of 8 days. In the group treated with enoxaparin, at 14 days there was a 14.2% incidence in the primary endpoint (death, AMI or emergency revascularization), as opposed to 16.6% in the group treated with UFH (relative risk ratio (RRR) = 15%; p = 0.03) ( Figure 2 ). However, these results could have been affected by a difference in the duration of treatment because the patients who were given UFH were treated for an average of 3 days, while the ones who were administered enoxaparin were treated for an average of 4.6 days. Given the fact that the divergence between the two curves starts precisely between day 3 and day 5, we can hypothesize that if UFH Figure 2 TIMI 11B 16 : primary endpoint incidence at 14 days (RRR = 15%, p = 0.03) and at 43 days (RRR = 12%, p = 0.049).
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At 43 days, a difference persists between the two treatments (17.3% vs 19.6%; RRR 12%; p = 0.049) that is the same as the difference observed at day 14 ( Figure 2 ).
These results are at odds with those of the FRISC II study, since the benefit is observed in the acute phase and does not increase by extending the enoxaparin treatment beyond 5 days. Furthermore, the hemorrhagic events had almost the same incidence in the two groups (UFH and enoxaparin) in the acute phase, whereas it was slightly higher in the chronic phase, in which enoxaparin was compared with placebo (2.9% vs 1.5%; p = 0.02).
A meta-analysis 17 of the two studies shows that the primary endpoint occurs in 12.8% of patients in the enoxaparin group and in 15.7% in the UFH group, with an OR of 0.79 (CI 0.69-0.90; p = 0.0005) at 14 days; these figures were 15.6% vs 18.8%, respectively, with an OR of 0.80 (CI 0.71-0.91; p = 0.0005) at 43 days ( Table 1 ). According to this analysis, 35 patients must be treated to avoid one endpoint event.
A very recent meta-analysis by Eikelboom et al 18 on the effects of heparin in acute coronary syndromes without ST elevation, has shown that the reduction in the risk of death or MI in aspirin-treated patients is 66% with LMWHs and 33% with UFH (both in comparison with placebo). However, no difference in efficacy and safety emerged between the two treatments in direct-comparison studies.
These results appear to be due to the pooling of positive and negative trends of studies using different heparins, patient populations and study design.
Angioplasty (PTCA) and intracoronary stenting
Percutaneous coronary interventions are burdened by a risk of acute and subacute thrombosis of 2-3%; this rate is higher if stenting is involved.
Numerous studies have evaluated the effects of UFH in PTCA for preventing thrombosis, but many of these are retrospective and none of them are fully conclusive. These studies are the basis for the recommendation that UFH should be given prior to coronary angioplasty or stent implantation: 10 000 IU as a bolus followed by additional boluses or an infusion sufficient to maintain the activated clotting time (ACT) longer than 300 s; as an alternative, weight-and sex-adjusted UFH doses can be used. 19 Thus, the question arises of whether or not the use of LMWH is advantageous in situations that are so uncertain.
A subanalysis of the REDUCE study, 20 which focused on the prevention of restenosis and not of thrombosis, appears to demonstrate that the use of reviparin can help reduce acute occlusion in the periprocedural phase better than UFH (3.9% vs 8.2%; p = 0.03). Other studies besides REDUCE assessed the possibility of administering UFH or LMWH in periods ranging from 28 days to 4 months in order to inhibit restenosis over the long term following PTCA, but none of them have yielded positive results (ERA, 21 FACT, 22 SHARP 23 ).
The use of intracoronary stents has a lower incidence of restenosis (30% less), but a higher incidence of thrombosis with respect to PTCA.
In the ENTICES study, 24 the use of enoxaparin plus ticlopidine plus ASA was more effective (stent thrombosis of 0% vs 7%, a composite endpoint of 5% vs 20%; p = 0.01) than a combined treatment with warfarin plus heparin plus ASA plus dipyridamole. Moreover, the latter treatment had a very high incidence of hemorrhagic complications, thus confirming the preceding data.
Another study on coronary stenting is ATLAST 25 (Antiplatelet Therapy versus Lovenox plus Antiplatelet Therapy for Patients with an Increased Risk of Stent Thrombosis Trial). The objective of this study is to compare the efficacy of combined therapy (ASA, ticlopidine and enoxaparin for 14 days) with antiplatelet treatment alone in patients with a high risk of stent thrombosis. In this study there was a trend toward improvement in the enoxaparin group, the primary endpoint being death, myocardial infarction, or urgent revascularization (1.8% vs 2.7%; p = NS).
Some interventional cardiologists are ill at ease in using LMWH instead of UFH for percutaneous coronary interventions (PCI) because they are accustomed to titrating the heparin dosing with the ACT. This concern will be overcome when it is shown that an amount of an LMWH is at least as effective and safe as titrated UFH, just as it occurred with the treatment of venous thromboembolism. A pilot study for the NICE trials has shown that this is the case. The NICE trials compare UFH versus enoxaparin (1 mg/kg, single intravenous bolus) in patients undergoing percutaneous coronary intervention. A pilot study 26 showed that angioplasty success rates, in-hospital ischemia, bleeding and vascular complications were similar in both groups, even if anticoagulation attained with enoxaparin was significantly lower than it was after UFH. By avoiding the need to perform the ACT, PCI performance could prove to be simplified and its safety may be enhanced. However, as acknowledged by the authors, the study was under-powered to show a difference in clinical outcome between the two groups.
The FRISC II study also addressed the issue of invasive management of unstable angina, which has been the subject of a separate publication. 10 This paper reported a 23% risk reduction (p = 0.045) of MI and a 22% risk reduction of death or MI (p = 0.031) at 6 months when compared with non-invasive management. The association of dalteparin did not influence the above results.
Peripheral arteriopathies
Little research has been done to investigate the potential applications of LMWH therapy for peripheral arterial pathologies. In particular, the few studies that have been published focus on defining its use as an adjuvant in the invasive treatment of arterial stenoses, with the goal of pre-Vascular Medicine 2000; 5: 251-258 venting periprocedural thrombosis and bypass or stent occlusion.
Prevention of bypass occlusions
The study published by Edmondson and colleagues in 1994 27 compares the efficacy of LMWH dalteparin vs ASA + dipyridamole in preventing the occlusion of femoralpopliteal bypass grafts. All 200 patients enrolled in the study were treated with dalteparin 2500 IU subcutaneously 2 h prior to surgery, followed by 2500 IU subcutaneously per day for the next 7 days. After the first week they were randomized to receive dalteparin 2500 IU per day or ASA 300 mg per day + dipyridamole 100 mg every 8 h for the next 3 months. Treatment efficacy was assessed by verifying bypass patency at 1, 3, 6 and 12 months (presence of peripheral pulse, symptoms, Doppler exam and, in dubious cases, angiography).
Analysis of the data has revealed improved bypass graft patency in the LMWH group starting at 3 months. This becomes even more evident at 6 months and persists until the end of the study.
In particular, at 6 months, 87% of the cases treated with dalteparin showed graft survival, as opposed to 72% of the patients treated with ASA + dipyridamole (54% fewer occlusions with LMWH). At 12 months, the superiority of dalteparin was confirmed with 78% patent bypasses in the LMWH group compared with 64% in the group treated with ASA + dipyridamole (39% fewer occlusions with LMWH) (Figure 3) .
Analysis of the subgroups reveals yet another interesting element: by stratifying the patients based on indication for surgery, there emerges a precise indication for the use of LMWH in patients undergoing salvage surgery.
In fact, while no significant differences between the two treatments emerged in the group of patients undergoing elective surgery for claudication, the superiority of LMWH was evident in the group of patients who underwent salvage surgery, with 82% of bypass grafts patent at 12 months in the LMWH group compared with only 45% in the group treated with ASA + dipyridamole ( 2 = 11.75; p = 0.0006) ( Figure 4) . 
Prevention of restenosis after stenting
A recent study by Strecker and colleagues 28 examines the efficacy of LMWH reviparin in preventing restenosis in femoropopliteal stents. The 42 enrolled patients who underwent stent implantation for stenosis (n = 24) or occlusion (n = 18) on a femoral (n = 27) or popliteal (n = 15) level were treated after the procedure with an infusion of 10 500 IU of reviparin over the course of 24 h, followed by 3500 IU subcutaneously twice a day for 23 days and, lastly, 100 mg a day of ASA for long-term treatment. The results seem to be encouraging: there is no early in-stent thrombosis, primary patency is 88% Ϯ 6% (at 1 year) and 74% Ϯ 10.1% (at 2 years). However, the lack of a control group does not allow any comparative assessments to be made and as a result, the study needs to be confirmed.
Prevention of intraoperative thrombosis
The use of LMWH vs UFH to achieve intraoperative anticoagulation during femorodistal reconstructive surgery was investigated by two randomized clinical studies. In the multicenter study conducted by Samama et al, 29 201 patients were randomized to receive an intravenous bolus of enoxaparin, 75 IU/kg (n = 100) or UFH, 50 IU/kg (n = 101), followed 8 h later by the subcutaneous administration of 75 IU/kg of enoxaparin or 150 IU/kg of UFH every 12 h for 10 days. The saphenous vein or the prosthesis used for the bypass was rinsed with enoxaparin (25 000 IU) or UFH (25 000 IU) in a 250-ml saline solution. Assessment of bypass graft patency at 10 Ϯ 2 days showed a significantly higher incidence of occlusions (p = 0.009) in the group treated with UFH (22%) compared with the one treated with enoxaparin (8%), without any differences with regard to hemorrhagic complications. The importance of these results is undoubtedly not negligible; nevertheless, it is important to highlight the unusually high occlusion rate in patients treated with UFH, which contrasts with other case studies reported in the literature, as well as the brevity of the follow-up period.
Another study, which was conducted by Swedenborg et al 30 parameters for hypercoagulability. Two patients from each group experienced early occlusion of the bypass graft, while another patient treated with UFH was operated again following hemorrhaging. The levels of fibrin monomer were significantly lower in the group treated with dalteparin during clamping.
In any event, the small number of cases in this sample makes it difficult to interpret the virtual equivalence between the two treatments emerging from these results.
Acute ischemic stroke
The use of heparin therapy in acute stroke is still open to debate. Although many studies have proven the efficacy of heparin and its derivatives in preventing venous thromboembolic events in stroke patients, there is no clear evidence concerning the efficacy of these drugs in reducing neurological damage as well as their safety as far as hemorrhagic risk is concerned. The International Stroke Trial (IST) 31 compared ASA and UFH (twice daily) alone and together. The results of this study suggest that UFH may lead to a slight decrease in the incidence of early ischemic events, but at the cost of a significant rise in hemorrhagic events. Considering its better therapeutic index, these results may improve using LMWH. However, there are only two important studies on this issue and their results are contradictory. The Kay study (FISS), 32 conducted in Hong Kong, compared nadroparin administered subcutaneously in high doses (4100 IU every 12 h) or low doses (4100 IU every 24 h) with placebo. The patients (a total of 306) were randomized and treated within 48 h of the onset of symptoms and for the following 10-day period. This study excluded patients with hemorrhages (mandatory CT scan), rapid improvement of neurological deficit or extremely serious clinical features. The primary endpoint was death or disability at 6 months, as assessed by the Activities of Daily Living scale; the secondary endpoints were death, hemorrhagic transformation of the infarction or other complications at 10 days, and death or disability at 3 months.
Whereas no significant differences were found in the secondary endpoint, the 6-month evaluation showed a significant difference between the group treated with high doses of nadroparin and those treated with placebo (p = 0.005). The percentage of deceased or disabled patients at 6 months was 45% in the high-dose group, 52% in the low-dose group and 65% in the placebo group ( Figure 5) .
These results led the authors to sustain the efficacy of the drug in improving long-term outcome. Nevertheless, a similar study (FISS b) with higher doses (6000 IU once or twice daily) and more patients, conducted recently by Büller in the West, did not confirm these expectations about drug efficacy (H Büller, personal communication).
A randomized controlled study of a low molecular weight heparinoid, the Trial of ORG 10172 in Acute Stroke Treatment (TOAST), was published in 1998. The aim of TOAST 33 was to evaluate the efficacy and safety of ORG 10172, administered intravenously in patients with acute ischemic stroke. The treatment began with a bolus within 24 h of the onset of symptoms and it was extended to continuous infusion for a total of 7 days, with dose adjustment aiming at monitoring anti-Xa plasmatic activity values 32 : results of each treatment group 6 months after randomization. There is a significant dosedependent reduction in the risk of death or disability at 6 months in patients treated with LMWH (p = 0.005). between 0.6 and 0.8 IU anti-Xa/ml. The primary endpoint was an assessment of the outcome at 3 months using a disability scale (Glasgow Outcome Scale and modified Barthel Index). The secondary endpoints were outcome and mortality at 7 days, recurrent stroke and systemic embolic events. The results of statistical analysis do not point to any significant differences between the two treatment groups for the secondary endpoints, although there was a positive trend at 7 days in the heparinoid group (59.2% vs 54.3% favorable outcome; p = 0.07) ( Figure 6 ).
Moreover, evaluation of the 3-month outcome (primary endpoint) does not show any significant differences in the overall data analysis. However, it is important to note that in the subgroup analysis, there is a significant efficacy in large-vessel disease (non-lacunar stroke). The risk of important hemorrhagic events and intracranial hemorrhage was greater in patients treated with the heparinoid, respectively 32 patients vs 10 (p Ͻ 0.005) and 14 vs 4 (p Ͻ 0.005). In short, there are few published studies, the results are contradictory, the treatment procedures and time frames are The recent HAEST study 34 has assessed efficacy and safety of the treatment of acute stroke in atrial fibrillation patients with LMWH (dalteparin 100 UI/kg subcutaneously twice a day) compared with ASA (100 mg every day) for 14 days. The frequency of recurrent ischemic stroke, death and functional outcome were not significantly different at 14 days and at 3 months. However, as acknowledged by the authors, the study cannot exclude the possibility of small, but still worthwhile, effects of either drugs.
Therefore, it is necessary to design and implement study projects that can yield definitive and more indicative results so that the subgroup of patients who would benefit most from treatment can be identified.
Are all LMWHs created equal?
This is the same question as the one recently posed for statins in the prevention of cardiovascular events. 35 As far as LMWHs are concerned, since their therapeutic ratio (antithrombotic vs hemorrhagic effect) is higher than it is with UFH by a small difference, it was observed that, when used for the prevention of venous thromboembolism, some LMWHs at a given dosage were more effective but not safer than UFH, while others were shown to be safer but not more effective. This is due to the fact that the physical and biochemical characteristics of the various LMWHs are different enough to exert varying clinical effects and that their dosage used in the different trials is not strictly comparable. 36 Differences in the depolymerization process used for the preparation of the various LMWHs result in differing mean molecular weight and/or distribution of the length of the constituting chains, and thus in varying anti-Xa to anti-IIa ratio (the longer the chain the lower the ratio). Moreover, specific changes or end-residues of fragments due to depolymerization may cause higher content in non-affine material for ATIII. Owing to these differences, the efficacy and safety of the different LMWHs cannot be transferred from one to another and, more importantly, doses must be set individually. Moreover, it is difficult to correlate the clinical efficacy and safety of the different LMWHs with their relevant pharmacodynamic or kinetic profiles.
The results of the clinical trials testing LMWHs in the setting of arterial thrombosis, and particularly for the treatment of unstable angina and non-Q-wave MI, favor enoxaparin much more clearly than dalteparin or nadroparin. However, it is not clear if this difference is due to the superior efficacy of one LMWH over the other at the specific dosage used in this particular setting of vascular disease and/or if it is due to differences inherent to the trial design, patient characteristics, dosage regimens, duration of treatment, timing and definition of end-point or PCI rates. Therefore, it would not be scientifically sound to compare results with the different LMWHs based on the current available studies. 37 Indeed, these differences are high enough to cause a balance of positive and negative trends in the studies comparing LMWHs with UFH in the pooled analysis performed by Eikelboom and colleagues. 18 An answer to the above question can only come from a direct comparison between different brands of LMWH in the various settings of arterial vascular disease.
Conclusions
The administration of UFH at full doses leads to a variable state of anticoagulation in different patients with either venous 38 or ischemic 39 pathologies. The treatment is usually adjusted based on APTT values, but the correlation between UFH plasma concentration and APTT is moderate and, as a result, only about 40% of UFH concentration variations reflect variations in APTT values. 40 This variability is due to individual differences in the plasma concentration of inhibitor proteins, some of which are 'acute phase' reactants. 41 LMWHs have a lower dose-effect variability, a longer half-life and a higher bioavailability; thus they can be administered in fixed doses or based on bodyweight, without requiring any control tests. The ensuing effect reproducibility is reflected in a better definition of the efficacy/risk ratio and thus in optimized treatment management.
In most indications, LMWHs have proved to be superior and at least as effective as UFH. However, it is essential to bear in mind that even if no superiority of LMWH over UFH should emerge, LMWHs nevertheless facilitate patient management because they are easy to administer and dose, and dosing does not require any laboratory verification.
